{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:32Z","timestamp":1787169512832,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Mycophenolic acid [MPA] is a powerful inhibitor of lymphocyte proliferation. Although this drug has been used across the globe for various maternal comorbidities, multiple concerns have been raised regarding its teratogenic effects. The Food and Drug Administration has changed its category to drug category D (evidence of fetal risk) in 2007. A wide range of congenital malformations in infants born to a mother using this medication have been described in the literature, but there is no specific set pattern of these malformations. We report a case of a female infant who had exposure to mycophenolate by maternal use during the initial phase of 1st trimester of her pregnancy and ended up having multiple congenital malformations. She was managed with multidisciplinary approach and was finally discharged home on respiratory support, after two months of hospital stay. The fact that our patient shared a pattern of congenital malformations with other reported cases who were exposed to mycophenolate in utero strongly suggests that mycophenolate had a causal role and that there might be an emerging fetal mycophenolate mofetil syndrome (FMMS).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijpam.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T11:59:27Z","timestamp":1646740767000},"page":"171-173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Fetal malformations associated with exposure to mycophenolic acid during the first trimester"],"prefix":"10.4103","volume":"9","author":[{"given":"Faisal","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faaezuddin","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna","family":"AbdulMuthalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Dammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Al Alaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Al Hazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelHakeem","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Bin","family":"Jabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdelAziz Bin","family":"Manea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyad","family":"Almidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240903","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/01.tp.0000186385.91735.5d","article-title":"A few memories from the beginning","volume":"80","author":"Sollinger","year":"2005","journal-title":"Supplement Transplantation"},{"key":"R2-4-20240903","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of myco- phenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R3-4-20240903","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R4-4-20240903","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclo-phosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R5-4-20240903","first-page":"S117","article-title":"Therapy of rheumatoid arthritis with mycophenolate mofetil","volume":"11","author":"Goldblum","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"R6-4-20240903","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/01.tp.0000252683.74584.29","article-title":"Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus","volume":"82","author":"Sifontis","year":"2006","journal-title":"Transplantation"},{"key":"R7-4-20240903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.32117","article-title":"In utero exposure to mycophenolate mofetil: a characteristic phenotype?","volume":"146A","author":"Perez-Aytes","year":"2007","journal-title":"Am J Med Genet"},{"key":"R8-4-20240903","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/S0091-6749(99)70259-9","article-title":"Teratology: general considerations and principles","volume":"103","author":"Finnell","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"R9-4-20240903","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1749-6632.1965.tb12260.x","article-title":"Embryological considerations IN teratology","volume":"123","author":"Wilson","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"R10-4-20240903","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Update on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Armenti","year":"2015","journal-title":"J Pediatr Genet"},{"key":"R11-4-20240903","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmg.2016.09.014","article-title":"Mycophe- nolate mofetil embryopathy: a newly recognized teratogenic syndrome","volume":"60","author":"Perez-Aytes","year":"2017","journal-title":"Eur J Med Genet"},{"key":"R12-4-20240903","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"American College of Rheuma-tology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"2020 Arthritis Care Res"},{"key":"R13-4-20240903","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology"},{"key":"R14-4-20240903","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0961203317749046","article-title":"Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015","volume":"27","author":"Bermas","year":"2018","journal-title":"Lupus"},{"key":"R15-4-20240903","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"R16-4-20240903","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R17-4-20240903","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus preg-nancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R18-4-20240903","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune- mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R19-4-20240903","first-page":"2919","article-title":"Canadian consensus con-ference on hydroxychloroquine","volume":"27","author":"Esdaile","year":"2000","journal-title":"J Rheumatol"},{"key":"R20-4-20240903","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0961203396005001151","article-title":"Antimalarial drugs in pregnancy: the North American experience","volume":"5","author":"Parke","year":"1996","journal-title":"Lupus"},{"key":"R21-4-20240903","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/0891693031000067296","article-title":"Immunosuppressive drug use in pregnancy","volume":"36","author":"Petri","year":"2003","journal-title":"Autoimmunity"}],"container-title":["International Journal of Pediatrics and Adolescent Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646722000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646722000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2022.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:42Z","timestamp":1787166462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2022.02.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijpam.2022.02.002","relation":{},"ISSN":["2352-6467"],"issn-type":[{"value":"2352-6467","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}